Novelties in the treatment of myelofibrosis and polycythemia vera 2021

Professor Srdan Verstovsek speak about the novelties and state of the art treatment presented at ASH 2021.

Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology

Patients with blood cancers, particularly those with more advanced disease, are at increased risk for serious COVID-19 outcomes, including an elevated chance of severe illness or death from infection, according to an analysis of more than 1,000 patients in the ASH RC COVID-19 Registry for Hematology.

Novelties in the treatment of multiple myeloma 2021

Professor Andrzej Jakubowiak speak about the novelties and state of the art treatment presented at ASH 2021.

Antibody Response to Vaccination with Myeloid and Lymphoid Neoplasms

Professor Susanne Saussele speaks about antibody response to vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms. In general, patients with hematological diseases are predisposed to develop infections. Severe COVID-19 infection associated with high mortality is more likely in these patient cohorts compared to the general population. Due to immune defects related to the primary disease and/or to immunosuppressive treatment regimes, vaccination efficacy may be reduced in patients with hematological diseases. So far, data on this area are limited.

Novelties on the treatment of non-Hodgkin lymphoma 2021

The main topics that Professor Umberto Vitolo speaks about: CAR T-cell studies, POLARIS study, R-CHOP timing.

Results from the Randomized Phase 3 Transform Study

Professor Manali Kamdar speaks about Lisocabtagene Maraleucel, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Versus Standard of Care with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation As Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma.